ReviewAdvances in experimental medicine and biology2025
Development of Stem Cell Data Systems and Associated Data Standards for Cell Therapy.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As cell-based therapies near widespread clinical use, robust data management systems are crucial for ensuring safety, efficacy, and regulatory compliance. This chapter reviews the ISO 8472 series, which focuses on data interoperability for stem cell applications, and highlights the complexities of managing clinical, manufacturing, and quality control data. It underscores the need for standardized frameworks to streamline data sharing, analysis, and validation. Additionally, emerging technologies like AI and blockchain are explored for their potential to revolutionize data management, enhance security, and improve automation. Furthermore, this chapter addresses challenges in implementing data standards in cell therapy manufacturing and ensuring transparency. It outlines strategies to foster collaboration among stakeholders, including regulatory bodies, biobanks, CROs, and manufacturers, to drive innovation and scalability. Establishing comprehensive standards and interoperable data systems is essential for building trust and facilitating the commercialization of stem cell therapies.
Indexed as
Identifiers
41136854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.